Professional Marketing briefs

Share this article:

While many physicians complain about being besieged by drug industry sales reps, some want more details, a survey by Industry Standard Research noted. The firm polled 118 cardiologists, oncologists, family practitioners and allergy/immunologists. The family medicine specialists and oncologists said they'd like to see more of the reps—to the tune of, on average, 1.5 extra details per week.

Human Genome Sciences is eliminating 150 positions due to slow sales of its drug Benlysta. H. Thomas Watkins told investors last week that the company was “pleased” with sales for the first few quarters, but that Wall Street has failed to understand the drug's trajectory and to price the company's stock accordingly.

ImpactRx added a voice-capture response enhancement to its POP 2.0 tool, allowing physicians to answer questions in their own voices on the firm's iPhone and iPad-connected longitudinal research panels.

PDI's Group DCA is partnering with Veeva Systems on a product that combines Group DCA's digital detailing platform and Veeva's cloud-based CRM product to “enable seamless synchronization of insights gained from all interactions with the customer.”
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro